CENTRAL TRUST Co - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
CENTRAL TRUST Co ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$67,254
-21.4%
988
-5.7%
0.00%0.0%
Q2 2023$85,549
+6.0%
1,048
-3.7%
0.00%0.0%
Q1 2023$80,720
-10.5%
1,0880.0%0.00%
-33.3%
Q4 2022$90,174
+10.0%
1,088
+275.2%
0.00%0.0%
Q3 2022$82,000
-18.0%
2900.0%0.00%0.0%
Q2 2022$100,000
-20.0%
2900.0%0.00%
-25.0%
Q1 2022$125,000
-16.7%
2900.0%0.00%0.0%
Q4 2021$150,000
+435.7%
290
+400.0%
0.00%
+300.0%
Q3 2021$28,000
+7.7%
580.0%0.00%0.0%
Q2 2021$26,0000.0%58
-14.7%
0.00%0.0%
Q1 2021$26,000
+8.3%
68
-9.3%
0.00%0.0%
Q4 2020$24,000
+26.3%
750.0%0.00%0.0%
Q3 2020$19,000
-9.5%
75
-3.8%
0.00%0.0%
Q2 2020$21,000
+10.5%
78
-22.0%
0.00%0.0%
Q1 2020$19,000
-13.6%
1000.0%0.00%0.0%
Q4 2019$22,000
+10.0%
1000.0%0.00%0.0%
Q3 2019$20,000
-4.8%
1000.0%0.00%0.0%
Q2 2019$21,000
-12.5%
100
-16.7%
0.00%0.0%
Q1 2019$24,000
-63.6%
120
-73.7%
0.00%
-75.0%
Q4 2018$66,000
-92.3%
457
-89.1%
0.00%
-92.0%
Q3 2018$859,000
+35.9%
4,207
-1.5%
0.05%
+25.0%
Q2 2018$632,000
-2.0%
4,2720.0%0.04%
-2.4%
Q1 2018$645,000
+7962.5%
4,272
+4754.5%
0.04%
+4000.0%
Q3 2015$8,000
-11.1%
880.0%0.00%0.0%
Q2 2015$9,0000.0%880.0%0.00%0.0%
Q1 2015$9,000
+12.5%
880.0%0.00%0.0%
Q4 2014$8,000880.00%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 46,500$16,119,0008.75%
Montanaro Asset Management Ltd 93,950$32,567,0004.90%
Jackson Square Partners, LLC 556,157$192,786,0004.50%
STONE RUN CAPITAL, LLC 22,405$7,767,0003.91%
Ownership Capital B.V. 655,654$227,276,0003.90%
Brown Capital Management 839,587$291,034,0003.90%
Sandhill Capital Partners LLC 97,382$33,757,0003.61%
DF DENT & CO INC 684,026$237,111,0003.34%
Westwind Capital 27,946$9,687,0003.17%
MAIRS & POWER INC 655,930$227,371,0002.72%
View complete list of BIO-TECHNE CORP shareholders